This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary Nectin-4 Therapeutic Antibody Development
Background of Nectin‑4
Nectin-4 expression is elevated in various cancers in companion animals, and its role in tumor cell proliferation, survival, and metastasis makes it a potent candidate for targeted cancer therapies. BioVenic offers veterinary Nectin-4 therapeutic antibody development services, encompassing the entire antibody development process from antigen preparation, animal immunization, to antibody discovery, characterization, and engineering, committed to providing high-quality support for the development of veterinary therapeutic antibodies targeting Nectin-4.
Background of Nectin‑4
| Full Name | Nectin cell adhesion molecule 4 |
|---|---|
| Aliases | EDSS1, LNIR, PRR4, PVRL4. |
| Target Profile | As a member of the Nectin family, Nectin-4 is a type I transmembrane glycoprotein involved in cell-cell adhesion and signaling processes. It features a typical Ig-like structure with an extracellular region, a transmembrane domain, and an intracellular tail. The extracellular region primarily binds with nectins or other proteins such as afadin on the surface of other cells, while its intracellular region participates in signal transduction. Nectin-4 plays a crucial role in cell migration, proliferation, and morphogenesis, especially in tissue development and regeneration. |
MoA of Nectin‑4
Nectin-4 significantly influences the initial step of cell-cell junction formation. Once interactions are established, proteins-catenin complexes are recruited to these adhesive sites. Subsequently, the Nectin/Afadin and E-cadherin/catenin complexes function through Afadin and α-catenin, respectively, activating a signaling cascade (c-Src, C3G, Crk, PI3K, and Vav2) that regulates molecules like Rap1, Cdc42, and Racs, leading to rearrangement of the actin cytoskeleton. In cancer progression, Nectin-4 can propagate signals through downstream pathways, enhancing tumor angiogenesis, proliferation, and migration, and triggering epithelial-mesenchymal transition.
Fig.1 Nectin-4, through its cis-interaction with ErbB2 and its trastuzumab-resistant splice variants, augments their activation and DNA synthesis.1,2
Application in Veterinary Therapeutics
Canine distemper virus utilizes Nectin-4 as a receptor. And overexpression of Nectin-4 is associated with tumor growth in canine pulmonary adenocarcinoma, prostate cancer, and mammary gland cancer. Considering Nectin-4 as a therapeutic target for companion animal cancer treatment has the ability to impede the role of Nectin-4 in tumor growth and metastasis.
Veterinary Nectin‑4 Therapeutic Antibody Development Services
Nectin-4 holds significant potential in the treatment of companion animal cancers. BioVenic offers veterinary Nectin-4 therapeutic antibody development services, encompassing the entire stages from antigen expression and antibody preparation to antibody characterization and validation. During the service process, our team utilizes advanced technologies such as hybridoma technology, single B-cell technology, and phage display technology for antibody discovery. Additionally, our species-specific antibody development service is tailored to meet the unique needs of different companion animals, reducing heterologous components in antibody samples to enhance safety.
Please click the link below for more information about our veterinary Nectin‑4 therapeutic antibody development services.
Fig.2 Antibody discovery and production methods: from mouse hybridoma to transgenic mice. (BioVenic Original)
Why Choose Us?
BioVenic offers a one-stop service for veterinary therapeutic antibody development, focusing not only on antibody manufacturing but also providing functional and safety assessments to meet therapeutic applications.
Our team employs a diverse range of technological methods to provide robust technical support in veterinary Nectin-4 therapeutic antibody development, ensuring the effective selection of antibodies with high specificity and affinity.
We specialize in species-specific antibody development services, such as for companion animals like canine and feline, reducing the immunogenicity and enhancing their therapeutic safety and efficacy.
The study of Nectin-4 is increasingly gaining importance in veterinary diseases, especially in oncological research. Antibodies targeting Nectin-4 have the potential to be therapeutic tools. BioVenic provides services for veterinary Nectin-4 therapeutic antibody development, assisting you in exploring the role of Nectin-4 in companion animal cancer treatment If you are interested in this service, please contact us immediately.
References
- Kedashiro, Shin, et al. "Nectin-4 cis-interacts with ErbB2 and its trastuzumab-resistant splice variants, enhancing their activation and DNA synthesis." Scientific reports 9.1 (2019): 18997.
- Image retrieved from Figure 8 "Nectin-4 cis-interacts with ErbB2 and its trastuzumab-resistant splice variants, enhancing their activation and DNA synthesis. "Kedashiro, Shin, et al., 2019, used under [CC BY 4.0], the image title was changed to "Nectin-4, through its cis-interaction with ErbB2 and its trastuzumab-resistant splice variants, augments their activation and DNA synthesis."